ArticleJournal of bone oncology2026
Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurately predicting response to neoadjuvant chemotherapy (NACT) in osteosarcoma remains challenging, as the gold standard-tumor necrosis rate can only be assessed postoperatively. The tumor immune microenvironment, accessible via pretreatment biopsy, holds promise for early prediction, but the specific role of tumor-associated neutrophils (TANs) in this setting is unexplored. Methods: TANs abundance in pretreatment biopsies was quantified as CD66b Results: A total of 168 patients were analysed. Higher TANs density was independently associated with poor NACT response (adjusted odds ratios for Q2-Q4: 4.41-8.12; all P < 0.05). A predictive model incorporating TANs density demonstrated good discrimination (training AUC: 0.75; testing AUC: 0.74), calibration (Hosmer-Lemeshow P = 0.42 in training, P = 0.306 in testing), and clinical utility across risk thresholds of 30-80%. Survival analysis indicated that elevated TANs density correlated significantly with worse overall survival (P = 0.038) and recurrence-free survival (P = 0.026), but not with metastasis-free or disease-free survival. Conclusion: This study is the first to confirm that TANs density in osteosarcoma biopsy specimens is negatively correlated with NACT response. The predictive model constructed based on this finding enables pretreatment risk stratification and early intervention in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.